Trial Profile
A Retrospective, cohort study to evaluate the treatment outcomes of nab-Paclitaxel/gemcitabine versus gemcitabine mono-therapy and FOLFIRINOX in patients with metastatic pancreatic adenocarcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Jun 2017
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Jun 2017 Results assessing treatment outcomes in nab-Paclitaxel/gemcitabine versus FOLFIRINOX (n=414), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2017 New trial record